AKT1 and prostate neoplasm: Here, by demonstrating that evolution from benign hyperplasia to invasive prostate tumors without concomitant AKT activation, this iBRAF* model offers the first genetic proof that MAPK activation alone is sufficient for initiation and progression to invasive PCA in vivo.